ArticleJournal of clinical psychopharmacology2016
A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials.
Article in Journal of clinical psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder.Journal of substance use and addiction treatment · 2024Trial
- Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship.Journal of enzyme inhibition and medicinal chemistry · 2024Review
- Potential Pharmacokinetic Interactions of Common Cardiovascular Drugs and Selected European and Latin American Herbal Medicines: A Scoping Review.Plants (Basel, Switzerland) · 2023Article
- 4-Anilinoquinazoline-based benzenesulfonamides as nanomolar inhibitors of carbonic anhydrase isoforms I, II, IX, and XII: design, synthesis,Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment ofJournal of enzyme inhibition and medicinal chemistry · 2022Article
- In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common "diuretic and masking agent" in doping.Archives of toxicology · 2022Article
- Inpatient Diuretic Management of Acute Heart Failure: A Practical Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Review
- Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence.Clinical pharmacology and therapeutics · 2020Article
- GC-NICI-MS analysis of acetazolamide and other sulfonamide (R-SOJournal of pharmaceutical analysis · 2020Article
- Methods to reduce the incidence of false negative trial results in substance use treatment research.Current opinion in psychology · 2019Review
- Brain tumor acidification using drugs simultaneously targeting multiple pH regulatory mechanisms.Journal of neuro-oncology · 2019Article
- Amphiphilic Acrylic Nanoparticles Containing the Poloxamer Star Bayfit® 10WF15 as Ophthalmic Drug Carriers.Polymers · 2019Article
- From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.Psychopharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
rationaleAccurate assessment of medication adherence is critical for determination of medication efficacy in clinical trials, but most current methods have significant limitations. This study tests a subtherapeutic (microdose) of acetazolamide as a medication ingestion marker because acetazolamide is rapidly absorbed and excreted without metabolism in urine and can be noninvasively sampled.
methodsIn a double-blind, placebo-controlled, residential study, 10 volunteers received 15 mg oral acetazolamide for 4 consecutive days. Acetazolamide pharmacokinetics were assessed on day 3, and its pharmacokinetic and pharmacodynamic interactions with a model medication (30 mg oxycodone) were examined on day 4. The rate of acetazolamide elimination into urine was followed for several days after dosing cessation.
resultsErythrocyte sequestration (half-life = 50.2 ± 18.5 h, mean ± SD, n = 6), resulted in the acetazolamide microdose exhibiting a substantially longer plasma half-life (24.5 ± 5.6 hours, n = 10) than previously reported for therapeutic doses (3-6 hours). After cessation of dosing, the rate of urinary elimination decreased significantly (F3,23 = 247: P < 0.05, n = 6) in a predictable manner with low intersubject variability and a half-life of 16.1 ± 3.8 h (n = 10). For each of 4 consecutive mornings after dosing cessation, the rates of urinary acetazolamide elimination remained quantifiable.There was no overall effect of acetazolamide on the pharmacodynamics, Cmax, Tmax, or elimination half-life of the model medication tested. Acetazolamide may have modestly increased overall oxycodone exposure (20%, P < 0.05) compared with one of the 2 days when oxycodone was given alone, but there were no observed effects of acetazolamide on oxycodone pharmacodynamic responses.
conclusionsCoformulation of a once-daily trial medication with an acetazolamide microdose may allow estimation of the last time of medication consumption for up to 96 hours postdose. Inclusion of acetazolamide may therefore provide an inexpensive new method to improve estimates of medication adherence in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.